Scantox
Scantox at a glance
Scantox is a leading European Contract Research Organisation (“CRO”) specialized in preclinical services that enable global pharmaceutical and biotech companies to progress drug development projects. Scantox offer a broad set of pre-clinical services focused on drug discovery, pharmacology and regulatory toxicology. Scantox was founded more than 45 years ago and has a long track-record of supporting its trusted clients with efficacy and safety drug testing. Impilo acquired Scantox in 2021 from Charles River and has during the ownership acquired 5 add-on companies, positioning the company for a broader set of growth opportunities with a larger value chain coverage.
Scantox facts
Specialist Pharma Services
January 2021
Lille Skensved, Denmark
Jeanet Løgsted (CEO)
Martin Amtoft (CFO)
Nicholas Hooge
Victor Steien
Frederikke Beck
Alexander From
300
Investment thesis
- Large and fragmented pre-clinical CRO market with relatively high barriers to entry
- Ability to quickly re-emerge and strengthen position as a vital part of the Nordic and European pharma and biotech community
- Opportunity to expand service portfolio within both in-vivo toxicology and in-vitro/ADME services
- Opportunity to pursue add-on M&A within pre-clinical drug development and drug discovery
UN SDG Goals
Other portfolio companies
Avia Pharma
Avia is a leading North European OTC/Rx platform
Stille
Stille is a well-established pioneer in the development of premium surgical instruments and advanced surgical tables
Decon
Decon develops, assembles, and distributes high-quality, power-assisted electrical solutions for wheelchairs